2025
SJR Q2
JCR Q3 · 2,5
14 matched articles
SCIE
Journal detail
Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers
- Country
- United Arab Emirates · Middle East
- Type
- journal
- ISSN
-
1568009618735576
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,726
- Quartile Q2
- H-Index 109
- Cites/doc 2,95
- Docs (3y) 243
- Cites (3y) 734
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,5
- 5Y JIF 2,5
- JCI 0,49
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cancer Research Q3
- Drug Discovery Q2
- Oncology Q3
- Pharmacology Q2
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Oncology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,726 | 2,5 | 2,5 | 0,49 | Q3 | 109 |
| 2024 | Q2 | Q2 | 0,722 | 3,5 | 2,9 | 0,53 | Q3 | 106 |
| 2023 | Q2 | Q3 | 0,65 | 2,3 | 3,1 | 0,45 | Q3 | 106 |
| 2022 | Q2 | Q3 | 0,687 | 3 | 3,5 | 0,45 | Q3 | 106 |
| 2021 | Q2 | Q4 | 0,732 | 2,9 | 3,5 | 0,49 | Q3 | 106 |
| 2020 | Q1 | Q3 | 0,972 | 3,4 | 3,1 | 0,49 | Q3 | 106 |
| 2019 | Q1 | Q3 | 0,893 | 2,9 | 2,9 | 0,57 | Q3 | 106 |
| 2018 | — | Q3 | — | 2,7 | 3,2 | 0,56 | Q3 | — |
| 2017 | Q1 | Q3 | 0,951 | 2,6 | 3,2 | 0,66 | Q3 | 106 |
| 2016 | Q1 | Q3 | 1,271 | 3 | 3,4 | — | — | 106 |
| 2015 | Q1 | Q2 | 1,569 | 3,7 | 3,4 | — | — | 106 |
| 2014 | Q1 | Q2 | 1,533 | 3,5 | 3,6 | — | — | 106 |
| 2013 | Q1 | Q2 | 1,585 | 3,6 | 3,9 | — | — | 106 |
| 2012 | Q1 | Q2 | 1,789 | 4 | 4,4 | — | — | 106 |
| 2011 | Q1 | Q1 | 2,137 | 4,3 | 4,3 | — | — | 106 |
| 2010 | Q1 | Q1 | 2,236 | 4,8 | 4,9 | — | — | 106 |
| 2009 | — | Q1 | — | 5,1 | 5,2 | — | — | — |
| 2008 | — | Q2 | — | 4,3 | — | — | — | — |
| 2007 | — | Q1 | — | 5,4 | — | — | — | — |
| 2006 | — | Q1 | — | 5,7 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q3 | Q3 | 204/333 |
| 2024 | ONCOLOGY | SCIE | Q2 | Q3 | 106/328 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q3 | 202/322 |
| 2022 | ONCOLOGY | SCIE | Q3 | Q3 | 157/241 |
| 2021 | ONCOLOGY | SCIE | Q4 | Q3 | 185/245 |
| 2020 | ONCOLOGY | SCIE | Q3 | Q3 | 159/242 |
| 2019 | ONCOLOGY | SCIE | Q3 | Q3 | 141/244 |
| 2018 | ONCOLOGY | SCIE | Q3 | Q3 | 136/230 |
| 2017 | ONCOLOGY | SCIE | Q3 | Q3 | 141/223 |
| 2016 | ONCOLOGY | SCIE | Q3 | — | 110/217 |
| 2015 | ONCOLOGY | SCIE | Q2 | — | 68/213 |
| 2014 | ONCOLOGY | SCIE | Q2 | — | 74/211 |
| 2013 | ONCOLOGY | SCIE | Q2 | — | 67/203 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 54/197 |
| 2011 | ONCOLOGY | SCIE | Q1 | — | 41/196 |
| 2010 | ONCOLOGY | SCIE | Q1 | — | 37/185 |
| 2009 | ONCOLOGY | SCIE | Q1 | — | 25/166 |
| 2008 | ONCOLOGY | SCIE | Q2 | — | 37/143 |
| 2007 | ONCOLOGY | SCIE | Q1 | — | 20/132 |
| 2006 | ONCOLOGY | SCIE | Q1 | — | 17/127 |